Full-Time

Histology Manager

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Biotechnology
Healthcare

Compensation Overview

$109k - $150kAnnually

+ Bonus + Incentives + Restricted Stock Units

Senior

San Diego, CA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary

You match the following Veracyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BA/BS degree; BS in chemical, physical, or biological science, or medical technology preferred
  • Minimum 5 years’ experience as a Histotechnologist or Histotechnician
  • Minimum 1 year supervising people
  • Certification: HT(ASCP) or HTL (ASCP)
  • Knowledge of CLIA, New York, CAP and OSHA regulatory requirements
  • Maintains continuing education units required for maintaining the BOC
Responsibilities
  • Supervision and oversight of the histology lab
  • Training personnel
  • Implementing workflow and software process improvements
  • Coordination of quality assurance program
  • Ensuring compliance with state and national regulatory agencies
  • Interfacing with other departments including laboratory, Pre-Analytical and the pathology, supply chain and client services
  • Maintaining efficient processes as they relate to company goals
  • Providing direct supervision to supervisors, technologists, technicians, associates, and assistants
  • Workload assignments, training, resolution of technical problems, staffing, scheduling, and other disciplinary measures
  • Performing the highest quality histological procedures related to the microtomy, mounting, and staining of specimens for microscopic interpretation
  • Preparing microscopic slides for diagnostic purposes, including embedding, microtomy, and mounting to include paraffin processed tissue
  • Maintaining records and documentation required to manage the daily workflow and provide QC/QA monitors
  • Troubleshooting areas of processing, microtomy, staining and equipment
  • Performing and documenting scheduled preventative maintenance
  • Performing training, competency, and evaluations as needed
  • Understanding and following all safety guidelines
  • Participating in all continuing education programs required to keep certification current, if applicable
  • Handling and disposing of hazardous non-hazardous materials
  • Performing all other assigned duties as directed by management
  • Flexing schedule to accommodate workload to include weekend coverage
  • Performing all duties according to guidelines outlined within the quality systems
  • Compliant with company policies, procedures, safety requirements and regulations
Desired Qualifications
  • Exposure to general laboratory environment conditions
  • Ability to follow detailed instructions and maintain accurate records
  • Strong attention to detail and organization skills
  • Basic computer skills, including data entry and use of LIMS
  • Excellent problem-solving skills
  • Excellent written and oral communication skills
  • Ability to work independently and exercise good judgement
  • Excellent teamwork and collaboration skills
  • Excellent interpersonal skills
  • Enthusiasm and an entrepreneurial spirit
  • Demonstrated self-starter
  • Excellent verbal and written communication skills
  • The ability to navigate efficiently through, or have familiarity with, various laboratory information systems (LIS) and have proficiency in Microsoft Office products (Excel, Word, Access and PowerPoint)

Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, to provide insights into the presence and progression of cancer. This information helps healthcare providers, including hospitals and clinics, make informed treatment decisions for their patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$69.4M

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Increasing demand for personalized medicine boosts genomic diagnostics growth.
  • AI integration enhances accuracy and speed of Veracyte's cancer diagnostics.
  • Regulatory support is improving for genomic testing, streamlining approvals.

What critics are saying

  • AI-based tests may have bias due to initial development on limited demographics.
  • MRD assay launch in 2026 may face reimbursement challenges with commercial payers.
  • ClearLab's 2026 launch may encounter significant market competition.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
MLO Online
Feb 17th, 2025
New Data at ASCO demonstrates the performance and clinical utility of Veracyte's Decipher Prostate and Decipher Bladder tests

Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.

Investing.com
Sep 4th, 2024
Veracyte expands board with two new members

SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Stock Titan
Sep 4th, 2024
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.